Literature DB >> 26087176

Prevalence of meconium ileus marks the severity of mutations of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene.

Annie Dupuis1,2, Katherine Keenan3, Chee Y Ooi4,5, Ruslan Dorfman6, Marci K Sontag7, Lutz Naehrlich8, Carlo Castellani9, Lisa J Strug2,10, Johanna M Rommens10,11, Tanja Gonska2,12.   

Abstract

RATIONALE: Meconium ileus (MI) is a perinatal complication in cystic fibrosis (CF), which is only minimally influenced by environmental factors. We derived and examined MI prevalence (MIP) scores to assess CFTR phenotype-phenotype correlation for severe mutations.
METHOD: MIP scores were established using a Canadian CF population (n = 2,492) as estimates of the proportion of patients with MI among all patients carrying the same CFTR mutation, focusing on patients with p.F508del as the second allele. Comparisons were made to the registries from the US CF Foundation (n = 43,432), Italy (Veneto/Trentino/Alto Adige regions) (n = 1,788), and Germany (n = 3,596).
RESULTS: The prevalence of MI varied among the different registries (13-21%). MI was predominantly prevalent in patients with pancreatic insufficiency carrying "severe" CFTR mutations. In this severe spectrum MIP scores further distinguished between mutation types, for example, G542X (0.31) with a high, F508del (0.22) with a moderate, and G551D (0.08) with a low MIP score. Higher MIP scores were associated with more severe clinical phenotypes, such as a lower forced expiratory volume in 1 second (P = 0.01) and body mass index z score (P = 0.04).
CONCLUSIONS: MIP scores can be used to rank CFTR mutations according to their clinical severity and provide a means to expand delineation of CF phenotypes.Genet Med 18 4, 333-340.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26087176     DOI: 10.1038/gim.2015.79

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  41 in total

Review 1.  Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis.

Authors:  M J Welsh; A E Smith
Journal:  Cell       Date:  1993-07-02       Impact factor: 41.582

2.  Spirometric reference values from a sample of the general U.S. population.

Authors:  J L Hankinson; J R Odencrantz; K B Fedan
Journal:  Am J Respir Crit Care Med       Date:  1999-01       Impact factor: 21.405

3.  New meconium biomarkers of prenatal methamphetamine exposure increase identification of affected neonates.

Authors:  Teresa R Gray; Tamsin Kelly; Linda L LaGasse; Lynne M Smith; Chris Derauf; Penny Grant; Rizwan Shah; Amelia Arria; William Haning; Sheri Della Grotta; Arthur Strauss; Barry M Lester; Marilyn A Huestis
Journal:  Clin Chem       Date:  2010-02-25       Impact factor: 8.327

4.  Identification of the M1101K mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene and complete detection of cystic fibrosis mutations in the Hutterite population.

Authors:  J Zielenski; T M Fujiwara; D Markiewicz; A J Paradis; A I Anacleto; B Richards; R H Schwartz; K W Klinger; L C Tsui; K Morgan
Journal:  Am J Hum Genet       Date:  1993-03       Impact factor: 11.025

5.  Correlation between genotype and phenotype in patients with cystic fibrosis.

Authors: 
Journal:  N Engl J Med       Date:  1993-10-28       Impact factor: 91.245

6.  Genetic determination of exocrine pancreatic function in cystic fibrosis.

Authors:  P Kristidis; D Bozon; M Corey; D Markiewicz; J Rommens; L C Tsui; P Durie
Journal:  Am J Hum Genet       Date:  1992-06       Impact factor: 11.025

7.  Association of a nonsense mutation (W1282X), the most common mutation in the Ashkenazi Jewish cystic fibrosis patients in Israel, with presentation of severe disease.

Authors:  T Shoshani; A Augarten; E Gazit; N Bashan; Y Yahav; Y Rivlin; A Tal; H Seret; L Yaar; E Kerem
Journal:  Am J Hum Genet       Date:  1992-01       Impact factor: 11.025

8.  Cystic fibrosis patients bearing both the common missense mutation Gly----Asp at codon 551 and the delta F508 mutation are clinically indistinguishable from delta F508 homozygotes, except for decreased risk of meconium ileus.

Authors:  A Hamosh; T M King; B J Rosenstein; M Corey; H Levison; P Durie; L C Tsui; I McIntosh; M Keston; D J Brock
Journal:  Am J Hum Genet       Date:  1992-08       Impact factor: 11.025

9.  Genetic differences between cystic fibrosis with and without meconium ileus.

Authors:  E Mornet; B Simon-Bouy; J L Serre; X Estivill; M Farrall; R Williamson; J Boue; A Boue
Journal:  Lancet       Date:  1988-02-20       Impact factor: 79.321

10.  Variation in MSRA modifies risk of neonatal intestinal obstruction in cystic fibrosis.

Authors:  Lindsay B Henderson; Vishal K Doshi; Scott M Blackman; Kathleen M Naughton; Rhonda G Pace; Jackob Moskovitz; Michael R Knowles; Peter R Durie; Mitchell L Drumm; Garry R Cutting
Journal:  PLoS Genet       Date:  2012-03-15       Impact factor: 5.917

View more
  14 in total

1.  Body composition and lung function in children with cystic fibrosis and meconium ileus.

Authors:  Artemis Doulgeraki; Argyri Petrocheilou; Glykeria Petrocheilou; George Chrousos; Stavros-Eleftherios Doudounakis; Athanasios G Kaditis
Journal:  Eur J Pediatr       Date:  2017-04-13       Impact factor: 3.183

Review 2.  Beyond pancreatic insufficiency and liver disease in cystic fibrosis.

Authors:  Stephanie Demeyer; Kris De Boeck; Peter Witters; Katrien Cosaert
Journal:  Eur J Pediatr       Date:  2016-04-07       Impact factor: 3.183

Review 3.  Cystic fibrosis: a clinical view.

Authors:  Carlo Castellani; Baroukh M Assael
Journal:  Cell Mol Life Sci       Date:  2016-10-05       Impact factor: 9.261

Review 4.  Cystic Fibrosis.

Authors:  Susanne Naehrig; Cho-Ming Chao; Lutz Naehrlich
Journal:  Dtsch Arztebl Int       Date:  2017-08-21       Impact factor: 5.594

Review 5.  Cystic fibrosis from the gastroenterologist's perspective.

Authors:  Chee Y Ooi; Peter R Durie
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-01-21       Impact factor: 46.802

6.  Guanylate cyclase 2C agonism corrects CFTR mutants.

Authors:  Kavisha Arora; Yunjie Huang; Kyushik Mun; Sunitha Yarlagadda; Nambirajan Sundaram; Marco M Kessler; Gerhard Hannig; Caroline B Kurtz; Inmaculada Silos-Santiago; Michael Helmrath; Joseph J Palermo; John P Clancy; Kris A Steinbrecher; Anjaparavanda P Naren
Journal:  JCI Insight       Date:  2017-10-05

Review 7.  The evidential statistical paradigm in genetics.

Authors:  Lisa J Strug
Journal:  Genet Epidemiol       Date:  2018-08-18       Impact factor: 2.135

8.  Genetic and phenotypic traits of children and adolescents with cystic fibrosis in Southern Brazil.

Authors:  Katiana Murieli da Rosa; Eliandra da Silveira de Lima; Camila Correia Machado; Thaiane Rispoli; Victória d'Azevedo Silveira; Renata Ongaratto; Talitha Comaru; Leonardo Araújo Pinto
Journal:  J Bras Pneumol       Date:  2018 Nov-Dec       Impact factor: 2.624

9.  Patient-reported outcomes in patients with cystic fibrosis with a G551D mutation on ivacaftor treatment: results from a cross-sectional study.

Authors:  Scott C Bell; Jochen G Mainz; Gordon MacGregor; Susan Madge; Julie Macey; Moshe Fridman; Ellison D Suthoff; Siva Narayanan; Nils Kinnman
Journal:  BMC Pulm Med       Date:  2019-08-13       Impact factor: 3.317

10.  Genetic association and transcriptome integration identify contributing genes and tissues at cystic fibrosis modifier loci.

Authors:  Jiafen Gong; Fan Wang; Bowei Xiao; Naim Panjwani; Fan Lin; Katherine Keenan; Julie Avolio; Mohsen Esmaeili; Lin Zhang; Gengming He; David Soave; Scott Mastromatteo; Zeynep Baskurt; Sangook Kim; Wanda K O'Neal; Deepika Polineni; Scott M Blackman; Harriet Corvol; Garry R Cutting; Mitchell Drumm; Michael R Knowles; Johanna M Rommens; Lei Sun; Lisa J Strug
Journal:  PLoS Genet       Date:  2019-02-26       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.